Skip to main content

Table 2 Primary and secondary efficacy and safety outcomes

From: A randomized phase 2B trial of vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations – results of a prematurely terminated study

Study variables Vancomycin (n = 7) Daptomycin (n = 7) All (n = 14)
Day-60 mortality 1 0 1
Microbiological failure 0 0 0
Recurrence 1 0 1
Time to microbiological clearance, days (median, IQR) 4 (3, 5) 4 (3, 7) 4 (3, 5)
Musculoskeletal toxicity 0 1 1
Nephrotoxicity 0 1 1
Study drug discontinued due to toxicity 1 1 2
Study drug discontinued due to worsening infection 0 0 0
Addition of a second MRSA agent due to worsening infection 0 0 0
  1. Data are number of cases, unless otherwise stated
  2. Abbreviations: IQR interquartile range, MRSA methicillin-resistant staphylococcus bacteremia